Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment options for older unfit patients with acute myeloid leukemia.

Future oncology (London, England) - 1 Mar 2021

Tang Hailong, Jia Shuangshuang, Bi Lei, Jia Weijing, Gao Guangxun

Abstract excerpt

Older acute myeloid leukemia patients usually experience a bleak outcome, especially those in the unfit group. For this unfit category, intensive chemotherapy and allogeneic stem cell transplantation are usually accompanied by higher early mortality, which results from higher risk genetic profiles and worse psychological and physiological conditions. The significant improvement in genetic technology recently has...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Activities of Daily Living
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Drug Resistance, Neoplasm

Share to Geriatric Assessment

Share to Leukemia, Myeloid, Acute

Share to Molecular Targeted Therapy

Share to Progression-Free Survival

Source

Identifiers

PMID: 33522289
DOI: 10.2217/fon-2020-0615

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment options for older unfit patients with acute myeloid leukemia.PMID 33522289Read ↗

How I treat acute myeloid leukemia in the era of new drugs.Semantic proximity Read ↗

Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question.Semantic proximity Read ↗

Evolving treatment strategies in patients with high-risk acute myeloid leukemia.Semantic proximity Read ↗

Latest Insights and Progress in the Clinical Management of Elderly Patients with Acute Myeloid Leukemia: From Genetic Advancements to Targeted TreatmentsSemantic proximity Read ↗

Innovative strategies for adverse karyotype acute myeloid leukemia.Semantic proximity Read ↗

A precision medicine approach to management of acute myeloid leukemia in older adults.Semantic proximity Read ↗

New Treatment Options for Older Patients with Acute Myeloid Leukemia.Semantic proximity Read ↗

Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?Semantic proximity Read ↗

Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrumSemantic proximity Read ↗

New agents for acute myeloid leukemia: is it time for targeted therapies?Semantic proximity Read ↗

Advancements and Challenges in the Treatment of AML.Semantic proximity Read ↗

Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New AgentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.